CS
AMED

Cannell & Spears’s Amedisys AMED Stock Holding History

Cannell & Spears’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,279
Closed -$756K – 224
2023
Q1 		$756K Sell
10,279
-15,141
-60% -$1.31M 0.07% 105
2022
Q4 		$2.12M Sell
25,420
-8,077
-24% -$728K 0.2% 61
2022
Q3 		$3.24M Sell
33,497
-180
-0.5% -$21.5K 0.32% 49
2022
Q2 		$3.54M Buy
33,677
+12,429
+58% +$1.59M 0.32% 49
2022
Q1 		$3.66M Sell
21,248
-1,631
-7% -$244K 0.27% 49
2021
Q4 		$3.7M Sell
22,879
-16,051
-41% -$2.58M 0.25% 53
2021
Q3 		$5.8M Buy
+38,930
New +$8.09M 0.42% 42

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Cannell & Spears's AMED Position: Q2 2023 in Review

Cannell & Spears sold out of Amedisys (AMED) in Q2 2023, closing a stake of 10,279 shares — an estimated $756K sold.

Cannell & Spears first reported a position in AMED in Q3 2021 and held it in 7 quarters. The position peaked at $5.8M in Q3 2021. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

  • Cannell & Spears reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
  • Cannell & Spears sold 10,279 Amedisys shares in Q2 2023, an estimated $756K.
  • Cannell & Spears first reported a position in Amedisys in Q3 2021 and held it in 7 quarters.
  • Cannell & Spears's Amedisys position peaked at $5.8M in Q3 2021.
  • 301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Cannell & Spears's 13F filing for Q2 2023, filed 14 Aug 2023.